New data show bimatoprost's capability to treat IOP

December 13, 2007

Westport, Ireland-According to a study published in Ophthalmology this month (bimatoprost) (Lumigan) alone is just as effective at lowering IOP as a fixed combination of latanoprost combined with timolol.

Westport, Ireland-According to a study published in Ophthalmology this month (bimatoprost) (Lumigan) alone is just as effective at lowering IOP as a fixed combination of latanoprost combined with timolol.

The randomized double-blind study compared the effects of bimatoprost and latanoprost combined with timolol on IOP over a 24-hour period.

It is outlined in the guidelines of the European Glaucoma Society that bimatoprost appears to be one of the effective, well-tolerated agents for the reduction of IOP in patients with primary open-angle glaucoma and ocular hypertension.

The patients that participated in the study either had glaucoma or ocular hypertension and were on a non-fixed combination of latanoprost and timolol for at least 3 months or on either latanoproast or timolol and not fully controlled prior to enrollment.